Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size
Clinical Cardiology, 04/27/2012Fogari R et al.
Telmisartan was more effective than amlodipine in preventing atrial fibrillation (AF) recurrences in hypertensive patients with paroxysmal AF.
The authors assigned 378 mild hypertensive outpatients in sinus rhythm, but with ≥2 episodes of AF in the previous 6 months, to 1 of 2 groups.
Group 1 comprised patients with LAD <40 mm in females and <45 mm in males.
Group 2 comprised patients with LAD >40 mm and <45 mm in females and >45 mm and <50 mm in males.
In both groups, patients were randomly treated with telmisartan or amlodipine for 1 year.
Systolic and diastolic blood pressure were similarly reduced by telmisartan and amlodipine in both groups.
The AF recurrence rate was significantly lower in the telmisartan–treated patients than in the amlodipine–treated patients in both group 1 (12 vs 39, P < 0.01) and group 2 (40 vs 59, P < 0.05).
Under telmisartan, the AF recurrence rate was significantly lower in group 1 than in group 2 (12.9% vs 42.1%, P < 0.05).
Time to a first AF relapse was significantly longer with telmisartan than with amlodipine in both group 1 (176 ± 94 days vs 74 ± 61 days, P < 0.05) and group 2 (119 ± 65 days vs 38 ± 35 days, P < 0.05).
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.